A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting 30 enrolled Sichuan Baili Pharmaceutical Co., Ltd. Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors.

Timeline

Start: 2024-04-19
Primary completion: 2026-05
Completion: 2026-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BL-M05D1	Unknown	—	Intravenous

Indications

No indication recorded.